Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.60 |
| ▸ | FAAH | O00519 | 2/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.52 |
| ▸ | RAD52 | P43351 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | DGKA | P23743 | 1/20 | 0.50 |
| ▸ | ADH1B | P00325 | 1/20 | 0.50 |
| ▸ | ADH1C | P00326 | 1/20 | 0.50 |
| ▸ | ADH1A | P07327 | 1/20 | 0.50 |
| ▸ | ADH4 | P08319 | 1/20 | 0.50 |
| ▸ | ADH7 | P40394 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5982054 | 1.00 | NAAA (0.60) | NAAAFAAHEPHX1RAD52NPSR1 | |
| SCHEMBL7004135 | 1.00 | NAAA (0.60) | NAAAFAAHEPHX1RAD52NPSR1 | |
| SCHEMBL11677656 | 1.00 | NAAA (0.60) | NAAAFAAHEPHX1RAD52NPSR1 | |
| SCHEMBL7672094 | 0.98 | NAAA (0.57) | NAAAFAAHEPHX1RAD52NPSR1 | |
| SCHEMBL872367 | 0.92 | ATM (0.50) | NAAAFAAHEPHX1RAD52NPSR1 | |
| SCHEMBL5067226 | 0.86 | NAAA (0.67) | NAAAFAAHEPHX1RAD52NPSR1 | |
| SCHEMBL5497221 | 0.86 | NAAA (0.67) | NAAAFAAHEPHX1RAD52NPSR1 | |
| SCHEMBL6948953 | 0.86 | NAAA (0.41) | NAAAFAAHEPHX1RAD52NPSR1 | |
| SCHEMBL11184931 | 0.86 | NAAA (0.67) | NAAAFAAHEPHX1RAD52NPSR1 | |
| SCHEMBL24595628 | 0.85 | NAAA (0.44) | NAAAFAAHEPHX1RAD52NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43858-E1 | Substituted cycloalkene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| CN-102552263-A | Methods of increasing endogenous erythropoietin EPO | FIBROGEN INC | 2012-07-11 | — | — | CN | disclosed |
| CN-102552262-A | Methods of increasing endogenous erythropoietin EPO | FIBROGEN INC | 2012-07-11 | — | — | CN | disclosed |
| CN-102552261-A | Methods of increasing endogenous erythropoietin EPO | FIBROGEN INC | 2012-07-11 | — | — | CN | disclosed |
| CN-102526045-A | Methods of increasing endogenous erythropoietin EPO | FIBROGEN INC | 2012-07-04 | — | — | CN | disclosed |
| CN-102526044-A | Methods of increasing endogenous erythropoietin EPO | FIBROGEN INC | 2012-07-04 | — | — | CN | disclosed |
| US-7935835-B2 | Substituted cycloalkene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20090233952-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1935879-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233952-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | CD40, LITAF, TNF | NAAA 4740/4885FAAH 3176/4885EPHX1 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.